Molecular Partners (MOLN): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
1 concentrated manager holds it with a median weight of 0.1%.
Who owns Molecular Partners?
Molecular Partners trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Montanova Capital, 10.6% (13G filed May 2, 2025) and UBS Asset Management, 5.8% (13G filed Jul 17, 2025). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were Montanova Capital (2.2 million ADRs), BVF (1.4 million ADRs) and Citadel Advisors (17,179 ADRs).
Which institutions hold the most Molecular Partners shares?
Per Form 13F filings as of Jun 30, 2026, in ADRs:
- 1. Montanova Capital: 2.2 million ADRs
- 2. BVF: 1.4 million ADRs
- 3. Citadel Advisors: 17,179 ADRs
- 4. Morgan Stanley: 367 ADRs
- 5. UBS Group: 279 ADRs
Sources:13G by Montanova Capital (May 2, 2025) ↗13G by UBS Asset Management (Jul 17, 2025) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Quarter flow (concentrated managers)
Change in managers (1 → 1): 0 opened · 0 exited = 0
Net flow in the quarter: $0K (0 shares) · bought $0 and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
Concentrated managers holding it
- BVF$5.1M0.1%
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Largest holders of MOLN (all 13F filers)
- Montanova Capital2.2 MInvestment firm0
- BVFconcentrated1.4 MInvestment firm0
- Citadel Advisors17 KQuant or multi-manager+17 K
- Morgan Stanley367Bank or trading desk0
- UBS Group279Bank or trading desk+279
- Shares
- 2.2 M
- Change
- 0
See more
- Type
- Investment firm
- Value
- $8.6M
- BVFconcentrated
- Shares
- 1.4 M
- Change
- 0
See more
- Type
- Investment firm
- Value
- $5.1M
- Shares
- 17 K
- Change
- +17 K
See more
- Type
- Quant or multi-manager
- Value
- $65.3K
- Shares
- 367
- Change
- 0
See more
- Type
- Bank or trading desk
- Value
- $1.4K
- Shares
- 279
- Change
- +279
See more
- Type
- Bank or trading desk
- Value
- $1.1K
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Insiders (Form 4)
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
- UBS Asset Management5.8%13Gfiling ↗Event: Sep 30, 2024 · filed: Jul 17, 2025
- Montanova Capital10.6%13Gfiling ↗Event: Jun 15, 2021 · filed: May 2, 2025
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers